CardioFocus announced the completion of successful clinical cases with its QuickShot Nav large-area focal pulsed field ablation (PFA) catheter.
Dr. Ante Anić performed the cases for the treatment of persistent AFib at KBC Split in Split, Croatia. They came as part of the Quick AF study evaluating the investigational PFA catheter. Anić serves as principal investigator for the study.
In a news release, Anić called QuickShot Nav “a highly versatile tool with a wide range of applications.”
“Its design allows for flexible manipulation and the ability to map and ablate with a single device,” Anić said. “This makes it an exciting addition to the field, as it requires fewer applications compared to traditional methods while maintaining precision and allowing physicians the flexibility to determine lesion locations. I am optimistic about the impact this device will have on clinical practice.”
Marlborough, Massachusetts-based CardioFocus designed QuickShot Nav to support safe, effective and efficient PVI ablation workflows with fewer applications required to achieve flexible lesion sets. It features a magnetic navigation sensor to facilitate compatibility with magnetically enabled electroanatomic mapping systems. QuickShot Nav also utilizes CardioFocus’ patented PFA waveform, Wave 1.
Quick AF plans to include remapping in the coming months to assess lesion durability and optimized outcomes, CardioFocus says. Then, it plans for a continuation into a broader pivotal trial later this year.
“We are grateful to Dr. Anić and his team at KBC Hospital, and we are thrilled to see the outstanding progress with QuickShot Nav. “This is another exciting advancement toward safe and effective treatments for atrial fibrillation. Our strategy for PFA is founded on research that led to the discovery of our proprietary and proven waveform and has now expanded into a portfolio of tools designed to help physicians improve patient outcomes,” said Steve Ogilvie, CEO of CardioFocus.
